Zogenix Reports Positive Results From Relday(TM) Phase 1 Clinical Trial

[at noodls] – Plans to Seek Partner and Accelerate Development of Once-Monthly Subcutaneous Formulation of Risperidone for Schizophrenia SAN DIEGO, Jan. 3, 2013 (GLOBE NEWSWIRE) — Zogenix Inc. (Nasdaq:ZGNX), a pharmaceutical … more

View todays social media effects on ZGNX

View the latest stocks trending across Twitter. Click to view dashboard

See who Zogenix is hiring next, click here to view